GlassScriptPhysician profile
Margaret Galvez
NPI 1417430018
$2,213.64
in general payments reported to CMS, 2019-2025
23 companies · $702 in 2025
The $702 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $744 · 2022: $370 · 2023: $114 · 2024: $284 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046 · Education: $53.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.83 |
| Education | $53.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $338.14 | 2021-2024 | Veozah |
| Janssen Biotech, INC. | $329.16 | 2021-2025 | Tremfya |
| Abbvie INC. | $303.06 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.75 | 2022-2025 | Xifaxan |
| Axonics, INC. | $146.16 | 2024 | Axonics |
| Biohaven Pharmaceutical Holding Company LTD. | $124.90 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.79 | 2022 | |
| Corcept Therapeutics | $114.31 | 2023 | Korlym |
| Antares Pharma, INC. | $66.97 | 2021 | |
| Glaxosmithkline, LLC. | $63.68 | 2022 | |
| Qol Medical, LLC | $56.35 | 2025 | Sucraid |
| Paratek Pharmaceuticals, INC. | $54.12 | 2025 | Nuzyra |
| Hollister Incorporated | $48.29 | 2021 | |
| Allergan, INC. | $46.09 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $44.80 | 2025 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dentsply Ih INC. | $23.14 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $19.29 | 2021 | |
| Myovant Sciences INC. | $18.61 | 2021 | |
| Pfizer INC. | $18.03 | 2025 | |
| Merck Sharp & Dohme LLC | $17.43 | 2021 | |
| Aimmune Therapeutics, INC. | $15.87 | 2025 | Zenpep |
| Celltrion USA INC. | $15.32 | 2025 | Vegzelma |
| 180 Medical, INC. | $14.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Galvez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.